BTIG Research initiated coverage on Spectral AI with a new price target
$MDAI
Medical/Dental Instruments
Health Care
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2024 | $4.00 | Buy | BTIG Research |
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration ("FDA"). 2026 Annual Meeting of Stockholders A total of 17,267,570 shares representing 54.3% of the Company's total shares outstanding were re
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States. The DeepView System is intended for use in burn care in various settings, including burn centers, trauma centers, and emergency departments. "We are pleased that the FDA has recognized our novel technology. I a
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
8-K - Spectral AI, Inc. (0001833498) (Filer)
8-K - Spectral AI, Inc. (0001833498) (Filer)
SCHEDULE 13G/A - Spectral AI, Inc. (0001833498) (Subject)
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration ("FDA"). 2026 Annual Meeting of Stockholders A total of 17,267,570 shares representing 54.3% of the Company's total shares outstanding were re
DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of David McGuire as the Company's Chief Financial Officer, effective May 4, 2026. "David's appointment as CFO is another important step in strengthening Spectral AI's financial leadership and strategic readiness as we prepare for commercialization of the DeepView® System," said Vincent S. Capone, Spectral AI's Chief Executive Officer. "David is a seasoned public company executive with experience in global markets, fin
DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set
Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026. "Our results for the 2026 first quarter reflected the progress we have made in developing our DeepView® System for burn indication under the base phase of our Project BioShield Contract with BARDA," said Vincent Capone, Chief
DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 12, 2026 after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results. Investors interested in participating in the live call can dial into the conference call as follows: 833-890-6620 – U.S.412-564-3789 – International In addit
Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 MillionCash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2025") and full year ("FY 2025") ended December 31, 2025 and provided an update on its ongoing activities related to the commercialization of its proprietary, AI-driven DeepView® System for burn indication. "2025 was a pivotal year fo
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)